Activin and Inhibin

CBR-470-1 is an inhibitor of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1) . CBR-470-1 is also a non-covalent Nrf2 activator. CBR-470-1 protects SH-SY5Y neuronal cells against MPP + -induced cytotoxicity through activation of the Keap1-Nrf2

CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC 50 s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.In VitroCC-115 inhibits PC-3 cells proliferation with an IC 50 of 138 nM. In a

CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC 50 s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.In VitroCC-115 inhibits PC-3 cells proliferation with an IC 50 of 138 nM. In a

CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC 50 s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.In VitroCC-115 inhibits PC-3 cells proliferation with an IC 50 of 138 nM. In a

CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC 50 s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.In VitroCC-115 inhibits PC-3 cells proliferation with an IC 50 of 138 nM. In a

CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK) . CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosisIn

CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK) . CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosisIn

CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK) . CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosisIn

CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK) . CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosisIn

CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK) . CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosisIn

CC-90005 is a potent, selective and orally active inhibitor of protein kinase C-θ (PKC-θ) , with an IC 50 of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC 50 =4440 nM). CC-90005 can inhibit T cell activation by inhibiting IL-2

CC-90005 is a potent, selective and orally active inhibitor of protein kinase C-θ (PKC-θ) , with an IC 50 of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC 50 =4440 nM). CC-90005 can inhibit T cell activation by inhibiting IL-2